其修饰有高亲和力的抗CD47纳米抗体（αCD47nb），该纳米抗体是重链单克隆抗体的最小抗原结合结构域（VHH），并结合肿瘤细胞表面CD47。通过体外 ...
与公司其他基于CD47的双特异性分子具有类似的结构。IMM4701具有稳健的抗肿瘤活性，在多种实体瘤模型中，IMM4701在3.0 mg/kg（~0.3 mg/kg人体等效剂量 ...
Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloid leukaemia (AML).
Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback